Tariquidar, a selective P-glycoprotein inhibitor, does not potentiate loperamide's opioid brain effects in humans despite full inhibition of lymphocyte P-glycoprotein

Anesthesiology

Volumn 109, Issue 6, 2008, Pages 1092-1099

  Kurnik, Daniel ^a   Sofowora, Gbenga G ^a   Donahue, John P ^a   Nair, Usha B ^a   Wilkinson, Grant R ^a   Wood, Alastair J J ^d   Muszkat, Mordechai ^b,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; LOPERAMIDE; PLACEBO; TARIQUIDAR; NARCOTIC ANALGESIC AGENT; QUINOLINE DERIVATIVE;

ADULT; ALERTNESS; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG METABOLISM; DRUG POTENTIATION; FATIGUE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; PUPIL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; T LYMPHOCYTE; BLOOD; BLOOD BRAIN BARRIER; BRAIN; COMPARATIVE STUDY; DRUG ANTAGONISM; LYMPHOCYTE; METABOLISM; PHYSIOLOGY;

ADULT; ANALGESICS, OPIOID; BLOOD-BRAIN BARRIER; BRAIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG SYNERGISM; FEMALE; HUMANS; LOPERAMIDE; LYMPHOCYTES; MALE; P-GLYCOPROTEIN; PUPIL; QUINOLINES; YOUNG ADULT;

EID: 58149292199     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e31818d8f28     Document Type: Article

References (35)

1. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000; 28:655-60
2. Kemper EM, Cleypool C, Boogerd W, Beijnen JH, van Tellingen O: The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. Cancer Chemother Pharmacol 2004; 53:173-8
3. Kemper EM, van Zandbergen AE, Cleypool C, Mos HA, Boogerd W, Beijnen JH, van Tellingen O: Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin Cancer Res 2003; 9:2849-55
4. Kemper EM, Verheij M, Boogerd W, Beijnen JH, van Tellingen O: Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. Eur J Cancer 2004; 40:1269-74
5. Letrent SP, Pollack GM, Brouwer KR, Brouwer KL: Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmaco-dynamics in the rat. Pharm Res 1998; 15:599-605
6. Letrent SP, Pollack GM, Brouwer KR, Brouwer KL: Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab Dispos 1999; 27: 827-34
7. Choo EF, Kurnik D, Muszkat M, Ohkubo T, Shay SD, Higginbotham JN, Glaeser H, Kim RB, Wood AJ, Wilkinson GR: Differential in vivo sensitivity to inhibition of p-glycoprotein located in lymphocytes, testes, and the blood-brain barrier. J Pharmacol Exp Ther 2006; 317:1012-8
8. Passchier J, Bender D, Lawrie KW, Fellows I, Matthews JC, Gee AD: [11C]Loperamide as a highly sensitive PET probe to assess changes in cerebral P-glycoprotein functionality (abstract). J Label Compd Radiopharm 2005; 48:545
9. Lee YJ, Maeda J, Kusuhara H, Okauchi T, Inaji M, Nagai Y, Obayashi S, Nakao R, Suzuki K, Sugiyama Y, Suhara T: In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil. J Pharmacol Exp Ther 2006; 316:647-53
10. Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC, Unadkat JD: Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 2005; 77: 503-14
11. Mackerer CR, Clay GA, Dajani EZ: Loperamide binding to opiate receptor sites of brain and myenteric plexus. J Pharmacol Exp Ther 1976; 199:131-40
12. Stahl KD, van Bever W, Janssen P, Simon EJ: Receptor affinity and pharmacological potency of a series of narcotic analgesic, anti-diarrheal and neuro-leptic drugs. Eur J Pharmacol 1977; 46:199-205
13. Schinkel AH, Wagenaar E, Mol CA, van Deemter L: P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97:2517-24
14. Kalvass JC, Graff CL, Pollack GM: Use of loperamide as a phenotypic probe of mdr1a status in CF-1 mice. Pharm Res 2004; 21:1867-70
15. Dagenais C, Graff CL, Pollack GM: Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol 2004; 67:269-76
16. Pauli-Magnus C, Feiner J, Brett C, Lin E, Kroetz DL: No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Clin Pharmacol Ther 2003; 74:487-98
17. Skarke C, Jarrar M, Schmidt H, Kauert G, Langer M, Geisslinger G, Lotsch J: Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 2003; 13:651-60
18. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ: Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000; 68:231-7
19. Tayrouz Y, Ganssmann B, Ding R, Klingmann A, Aderjan R, Burhenne J, Haefeli WE, Mikus G: Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. Clin Pharmacol Ther 2001; 70:405-14
20. MukwayaG, MacGregorT, Hoelscher D, HemingT, Legg D, Kavanaugh K, Johnson P, SaboJP, McCallister S: Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. Antimicrob Agents Chemother 2005; 49:4903-10
21. Stewart A, Steiner J, Mellows G, Laguda B, Norris D, Bevan P: Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res 2000; 6:4186-91
22. 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin Cancer Res 2003; 9:650-6
23. Xenova: Tariquidar (XR-9576): P-glycoprotein Pump Inhibitor (investigator brochure). Slough, United Kingdom, Xenova, 2005
24. Hall JE, Uhrich TD, Ebert TJ: Sedative, analgesic and cognitive effects of clonidine infusions in humans. BrJ Anaesth 2001; 86:5-11
25. He H, Sadeque A, Erve JC, Wood AJ, Hachey DL: Quantitation of loperamide and N-demethyl-loperamide in human plasma using electrospray ionization with selected reaction ion monitoring liquid chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 2000; 744:323-31
26. Donahue JP, Dowdy D, Ratnam KK, Hulgan T, Price J, Unutmaz D, Nicotera J, Raffanti S, Becker M, Haas DW: Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy. Clin Pharmacol Ther 2003; 73:78-86
27. Rowland M, Tozer TN: Clinical Pharmacokinetics: Concepts and Applications, 3rd edition. Philadelphia, Lippincott Williams & Wilkins, 1995
28. Hsiao P, Sasongko L, Link JM, Mankoff DA, Muzi M, Collier AC, Unadkat JD: Verapamil P-glycoprotein transport across the rat blood-brain barrier: Cyclospor-ine, a concentration inhibition analysis, and comparison with human data. J Pharmacol Exp Ther 2006; 317:704-10
29. Trambas C, Wang Z, Cianfriglia M, Woods G: Evidence that natural killer cells express mini P-glycoproteins but not classic 170 kDa P-glycoprotein. Br J Haematol 2001; 114:177-84
30. Demeule M, Jodoin J, Gingras D, Beliveau R: P-glycoprotein is localized in caveolae in resistant cells and in brain capillaries. FEBS Lett 2000; 466:219-24
31. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39:361-98
32. Skarke C, Jarrar M, Erb K, Schmidt H, Geisslinger G, Lotsch J: Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine. Clin Pharmacol Ther 2003; 74:303-11
33. Kharasch ED, Hoffer C, Whittington D, Sheffels P: Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin Pharmacol Ther 2003; 74:543-54
34. Kim KA, Chung J, Jung DH, Park JY: Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol 2004; 60:575-81
35. Thummel KE, Wilkinson GR: In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998; 38:389-430